Pseudotyped virus neutralization assay

CG Christian Gaebler
ZW Zijun Wang
JL Julio C. C. Lorenzi
FM Frauke Muecksch
SF Shlomo Finkin
MT Minami Tokuyama
AC Alice Cho
MJ Mila Jankovic
DS Dennis Schaefer-Babajew
TO Thiago Y. Oliveira
MC Melissa Cipolla
CV Charlotte Viant
CB Christopher O. Barnes
YB Yaron Bram
GB Gaëlle Breton
TH Thomas Hägglöf
PM Pilar Mendoza
AH Arlene Hurley
MT Martina Turroja
KG Kristie Gordon
KM Katrina G. Millard
VR Victor Ramos
FS Fabian Schmidt
YW Yiska Weisblum
DJ Divya Jha
MT Michael Tankelevich
GM Gustavo Martinez-Delgado
JY Jim Yee
RP Roshni Patel
JD Juan Dizon
CU Cecille Unson-O’Brien
IS Irina Shimeliovich
DR Davide F. Robbiani
ZZ Zhen Zhao
AG Anna Gazumyan
RS Robert E. Schwartz
TH Theodora Hatziioannou
PB Pamela J. Bjorkman
SM Saurabh Mehandru
PB Paul D. Bieniasz
MC Marina Caskey
MN Michel C. Nussenzweig
ask Ask a question
Favorite

Fourfold serially diluted plasma from individuals convalescent from COVID-19, or monoclonal antibodies, were incubated with SARS-CoV-2 pseudotyped virus for 1 h at 37 °C. The mixture was subsequently incubated with 293TACE2 cells for 48 h, after which cells were washed with PBS and lysed with Luciferase Cell Culture Lysis 5× reagent (Promega). Nanoluc luciferase activity in lysates was measured using the Nano- Glo Luciferase Assay System (Promega) with the Glomax Navigator (Promega). The obtained relative luminescence units were normalized to those derived from cells infected with SARS-CoV-2 pseudotyped virus in the absence of plasma or monoclonal antibodies. The half-maximal inhibitory concentration for plasma (NT50) or monoclonal antibodies (IC50) was determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top = 1, bottom = 0) (GraphPad Prism).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A